Motor neuron disease is a neurodegenerative disease characterized by loss of upper motor neuron in the motor cortex and lower motor neurons in the brain stem and spinal cord. Death occurs 2-4 years after the onset of the disease. A complex interplay of cellular processes such as mitochondrial dysfunction, oxidative stress, excitotoxicity, and impaired axonal transport are proposed pathogenetic processes underlying neuronal cell loss. Currently evidence exists for the use of riluzole as a disease modifying drug; multidisciplinary team care approach to patient management; noninvasive ventilation for respiratory management; botulinum toxin B for sialorrhoea treatment; palliative care throughout the course of the disease; and Modafinil use for fatigue treatment. Further research is needed in management of dysphagia, bronchial secretion, pseudobulbar affect, spasticity, cramps, insomnia, cognitive impairment, and communication in motor neuron disease.
Keyphrases
- palliative care
- spinal cord
- oxidative stress
- botulinum toxin
- healthcare
- spinal cord injury
- stem cells
- physical activity
- emergency department
- chronic pain
- dna damage
- mesenchymal stem cells
- single cell
- case report
- multiple sclerosis
- depressive symptoms
- functional connectivity
- extracorporeal membrane oxygenation
- health insurance
- mechanical ventilation
- bone marrow
- smoking cessation
- heat stress